Yeast oropharyngeal colonization in human immunodeficiency virus-infected patients in central taiwan

Mycopathologia. 2014 Jun;177(5-6):309-17. doi: 10.1007/s11046-014-9753-5. Epub 2014 May 8.

Abstract

A prospective, cross-sectional study was conducted at a medical center in central Taiwan to understand the prevalence, associated factors, and microbiologic features for oropharyngeal yeast colonization in human immunodeficiency virus-infected outpatients. Oral yeast colonization was detected in 127 (45 %) patients, including 21 (16.5 %) colonized by more than one species. Of the 154 isolates, Candida albicans was the most common species (114, 74 %), followed by Candida dubliniensis (10, 6.5 %), Candida glabrata (10, 6.5 %), Candida tropicalis (7, 4.5 %), and 13 others. We found that receiving antituberculous drug (p = 0.046) or atazanavir (p = 0.045) was two predictors for patients colonized by non-C. albicans species (p = 0.005) and risking mixed yeast colonization (p = 0.009). Even though our data showed that clinical antifungal drugs remained effective in vitro against the colonizing yeasts, the increased mixed yeast colonization indicates a potential issue for controlling mixed infections in hospital settings.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / immunology
  • AIDS-Related Opportunistic Infections / microbiology*
  • Adult
  • Antifungal Agents / therapeutic use
  • CD4 Lymphocyte Count
  • Candida / classification
  • Candida / drug effects
  • Candida / genetics
  • Candida / isolation & purification*
  • Candidiasis / drug therapy
  • Candidiasis / immunology
  • Candidiasis / microbiology*
  • Cross-Sectional Studies
  • Female
  • Fluconazole / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Oropharynx / microbiology*
  • Prospective Studies
  • Taiwan

Substances

  • Antifungal Agents
  • Fluconazole